Sentences with phrase «development of active disease»
Although people with latent tuberculosis can not spread the disease, the ability to test for increased genetic susceptibility to development of active disease could lead to unfair treatment of specific subpopulations that are already marginalized, and could allow familiar ethical issues surrounding the justifiability of ethnic stratification to surface [100][103].
https://genomemedicine.biomedcentral.com/ Not exact matches
less than or equal to lamivudine Acquired Immune Deficiency Syndrome Antiretroviral therapy, usually means 1 - 2 drugs, used in early studies Antiretroviral zidovudine (also known as ZDV) Breastfeeding Baby Friendly Hospital Initiative Breastfeeding and HIV International Transmission Study Combined antiretroviral therapy Centers for Disease Control and Prevention Deoxyribonucleic Acid Exclusive Breastfeeding Enzyme Linked Immunosorbent Assay Food and Agrigulture Organization Fixed dose combination ART, e.g., lamividine, stavudine, and nevirapine Highly Active Antiretroviral Therapy, 3 or more drugs for more effective treatment used in later studies Human Immunodeficiency virus International Atomic Energy Agency Infant feeding Infant and young child feeding Lopinavir cubic millimetre Mother - to - Child Transmission of HIV Non-governmental organization Nevirapine Polymerase Chain Reaction People Living with HIV Prevention of Mother - to - Child Transmission Replacement Feeding Ritonavir Ribonucleic acid, one of the three major macromolecules (along with DNA and proteins) that are essential for all known forms of life single dose NVP United Nations Agencies Joint United Nations Programme on HIV / AIDS United Nations Population Fund United Nations Commissioner for Refugees United Nations Children's Fund U.S. Agency for International Development World Alliance for Breastfeeding Action United Nations World Food Programme World Health Assembly WHO 2010 Guidelines on HIV and infant feeding World Health Organization Zidovudine (same drug as AZT)
An active international research has been carried out for several years in order to identify candidate genes which explain the origin and development of the disease.
People with fewer socioeconomic resources — less education, lower income — have less healthy diets, may be less physically active and have poorer quality sleep, all of which lead to the early development of heart disease risk factors.
By developing blood biomarkers and «immunologic signatures» related to antigen - specific T - cell responses, the researchers hope to identify individuals with latent TB infection who are at greatest risk for progression to active disease, allowing development of prevention strategies to target those at highest risk in areas with high rates of infection (usually low - and middle - income countries), as well as high income countries such as the U.S., where factors such as recent infection and HIV co-infection are associated with an increased risk of progression to active TB.
The lack of knowledge and tools highlights the importance of ongoing research leading to the development of better diagnostic tests and biomarkers that can predict which patients are at risk for progression from latent to active disease, as well as better - tolerated treatment regimens for latent TB infections, note the authors.
Table 1: Selection, Design & Construction of HSV - based Oncolytic Viruses Table 2: Selection, Design & Construction of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisitions
On her blog, Despite Lupus, you can read about ongoing developments in the treatment of the disease and Sarah's personal stories of living life with lupus, as well as engage with her very active community of followers.
Academy of Nutrition Dietetics Active Schools Alliance for a Healthier Generation American Academy of Pediatrics American Association for Health Education American Association of Family & Consumer SciencesAmerican Cancer Society American College of Sports Medicine American Diabetes Association American Federation of Teachers American Heart Association American Public Health Association American School Health Association Association for Supervision and Curriculum Development Association of State and Territorial Health Officials Association of State Public Health Nutritionists Centers for Disease Control and Prevention Council of Chief State School Officers Directors of Health Promotion and Education Family, Career & Community Leaders of America Food Research and Action Center Healthy Kids Challenge KaBOOM!
In addition to serving as the attending neurosurgical clinician at the Veterinary Medical Teaching Hospital, he was an active researcher for the development of treatments of neurodegenerative disease that affect both young dogs and children.
It's just the beginning... We are committed to an active program of continued research and development of faster, simpler, less - expensive testing procedures for all forms of retinal disease as well as for dozens of other genetic diseases that affect dogs.
On her blog, Despite Lupus, you can read about ongoing developments in the treatment of the disease and Sarah's personal stories of living life with lupus, as well as engage with her very active community of followers.
On her blog, Despite Lupus, you can read about ongoing developments in the treatment of the disease and Sarah's personal stories of living life with lupus, as well as engage with her very active community of followers.